EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma

Daniel Dubinski, Sae-Yeon Won, Martin Voss, Fee Keil, Wolfgang Miesbach, Bedjan Behmanesh, Max Dosch, Peter Baumgarten, Joshua D Bernstock, Volker Seifert, Thomas M Freiman, Florian Gessler

Neurosurgical Review · 2022-02 · 45 (1) · 451-457

DOI: 10.1007/s10143-021-01539-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Review, online erschienen am 26.04.2021. Verfasst von Daniel Dubinski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University Hospital, Goethe University, Schleusenweg 2-16, 60598, Frankfurt, Germany. danieldubinski@gmail.com. Hauptthemen laut MEDLINE: Glioblastoma, Pulmonary Embolism. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events. To date, only limited data on anticoagulation management after pulmonary embolism (PE) in GBM is available and the sporadic use of DOACs remains off-label. A retrospective cohort analysis of patients with GBM and postoperative, thoracic CT scan confirmed PE was performed. Clinical course, follow-up at 6 and 12 months and the overall survival (OS) were evaluated using medical charts and neuroradiological data. Out of 584 GBM patients, 8% suffered from postoperative PE. Out of these, 30% received direct oral anticoagulants (DOACs) and 70% low-molecular-weight heparin (LMWH) for therapeutic anticoagulation. There was no significant difference in major intracranial hemorrhage (ICH), re-thrombosis, or re-embolism between the two cohorts. Although statistically non-significant, a tendency to reduced mRS at 6 and 12 months was observed in the LMWH cohort. Furthermore, patients receiving DOACs had a statistical benefit in OS. In our analysis, DOACs showed a satisfactory safety profile in terms of major ICH, re-thrombosis, and re-embolism compared to LMWH in GBM patients with postoperative PE. Prospective, randomized trials are urgent to evaluate DOACs for therapeutic anticoagulation in GBM patients with PE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPulmonary EmbolismAnticoagulantsHeparin, Low-Molecular-WeightHumansProspective StudiesRetrospective Studies

Stichwörter der Autor:innen

Direct oral anticoagulationGlioblastoma survivalLow-molecular-weight heparinPulmonary embolismTherapeutic anticoagulation

Substanzen

AnticoagulantsHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • Department of Neurosurgery, University Hospital, Goethe University, Schleusenweg 2-16, 60598, Frankfurt, Germany. danieldubinski@gmail.com.
  • Department of Neurosurgery, University Hospital, Goethe University, Schleusenweg 2-16, 60598, Frankfurt, Germany.
  • Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany.
  • Institute of Neuroradiology, University Hospital, Goethe University, Frankfurt, Germany.
  • Department of Hemostaseology and Transfusion Medicine, University Hospital, DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH, Frankfurt, Germany.
  • Department of Neurosurgery, Birgham and Women's, Harvard Medical School, Boston, MA, USA.

Förderung

  • Johann Wolfgang Goethe-Universität, Frankfurt am Main

Zitieren

APA

Dubinski, D., Won, S. Y., Voss, M., Keil, F., Miesbach, W., Behmanesh, B., Dosch, M., Baumgarten, P., Bernstock, J. D., Seifert, V., Freiman, T. M., & Gessler, F. (2022). Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma. Neurosurgical Review, 45(1), 451-457. https://doi.org/10.1007/s10143-021-01539-9

Vancouver

Dubinski D, Won SY, Voss M, Keil F, Miesbach W, Behmanesh B, et al. Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma. Neurosurgical Review. 2022;45(1):451-457. doi:10.1007/s10143-021-01539-9

BibTeX
@article{Dubinski2022,
  author = {Dubinski, Daniel and Won, Sae-Yeon and Voss, Martin and Keil, Fee and Miesbach, Wolfgang and Behmanesh, Bedjan and Dosch, Max and Baumgarten, Peter and Bernstock, Joshua D and Seifert, Volker and Freiman, Thomas M and Gessler, Florian},
  title = {Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma},
  journal = {Neurosurgical Review},
  year = {2022},
  volume = {45},
  number = {1},
  pages = {451--457},
  doi = {10.1007/s10143-021-01539-9}
}
Kostenlos starten →